tech
February 13, 2026
Why universal gene synthesis screening protects American biotech
In an era when Washington seems incapable of finding common ground on virtually any issue, it’s notable to encounter a policy area where stakeholders across the political spectrum agree. Gene synthesis screening has emerged as one of those increasingly rare issues with genuine bipartisan momentum, where economic and security interests and industry expertise all point in the same direction. A recent bipartisan bill, the Biosecurity Modernization and Innovation Act, outlines an ambitious vision for comprehensive gene synthesis screening standards. To understand why this matters, we need to start with the technology itself.
TL;DR
- Gene synthesis screening has bipartisan momentum in Washington due to economic and security alignment.
- The U.S. leads the global DNA synthesis market, projected to reach $9.30 billion by 2034.
- Advancements in AI pose new risks, potentially allowing harmful sequences to evade current screening methods.
- Industry-led initiatives, like the International Gene Synthesis Consortium, have developed voluntary screening protocols.
- Lack of standardized requirements creates an uneven playing field for companies investing in robust screening.
- Both the Biden and Trump administrations have taken executive actions to strengthen gene synthesis screening.
- Several bipartisan bills in Congress aim to establish mandatory screening standards and verification systems.
- Key improvements include robust verification, addressing split-order vulnerabilities, and reducing minimum screenable fragment lengths.
Continue reading the original article